449 related articles for article (PubMed ID: 7510574)
1. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
2. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
Leysen JE; Janssen PM; Schotte A; Luyten WH; Megens AA
Psychopharmacology (Berl); 1993; 112(1 Suppl):S40-54. PubMed ID: 7530377
[TBL] [Abstract][Full Text] [Related]
3. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
4. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
[TBL] [Abstract][Full Text] [Related]
6. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
7. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.
Schotte A; Bonaventure P; Janssen PF; Leysen JE
Jpn J Pharmacol; 1995 Dec; 69(4):399-412. PubMed ID: 8786644
[TBL] [Abstract][Full Text] [Related]
8. Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study.
Hall H; Halldin C; Nyberg S; Farde L; Sedvall G
Eur Neuropsychopharmacol; 1995 Mar; 5(1):19-25. PubMed ID: 7542051
[TBL] [Abstract][Full Text] [Related]
9. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.
Sumiyoshi T; Kido H; Sakamoto H; Urasaki K; Suzuki K; Yamaguchi N; Mori H; Shiba K; Yokogawa K
Pharmacol Biochem Behav; 1994 Mar; 47(3):553-7. PubMed ID: 7516078
[TBL] [Abstract][Full Text] [Related]
10. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro.
McCormick PN; Kapur S; Graff-Guerrero A; Raymond R; Nobrega JN; Wilson AA
Neuropsychopharmacology; 2010 Jul; 35(8):1826-35. PubMed ID: 20410873
[TBL] [Abstract][Full Text] [Related]
11. Survey on the pharmacodynamics of the new antipsychotic risperidone.
Megens AA; Awouters FH; Schotte A; Meert TF; Dugovic C; Niemegeers CJ; Leysen JE
Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
[TBL] [Abstract][Full Text] [Related]
12. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
[TBL] [Abstract][Full Text] [Related]
13. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
14. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
16. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
17. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
18. Effects of risperidone, clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons of the rat brain.
Bruggeman R; Westerink BH; Timmerman W
Eur J Pharmacol; 1997 Apr; 324(1):49-56. PubMed ID: 9137912
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors.
Czyrak A; Jaros T; Moryl E; Maj J
Pharmacopsychiatry; 1993 Mar; 26(2):53-8. PubMed ID: 7690975
[TBL] [Abstract][Full Text] [Related]
20. Effects of atypical antipsychotic agents on social behavior in rodents.
Corbett R; Hartman H; Kerman LL; Woods AT; Strupczewski JT; Helsley GC; Conway PC; Dunn RW
Pharmacol Biochem Behav; 1993 May; 45(1):9-17. PubMed ID: 7685916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
